SK bioscience has announced that it will advance a novel respiratory syncytial virus (RSV) preventive monoclonal antibody under a licence agreement with the Gates Medical Research Institute (Gates MRI). The clinical-stage candidate is intended for the prevention of RSV infection
AstraZeneca began trading on the New York Stock Exchange on Monday, February 2, 2026, marking a significant shift in the pharmaceutical giant’s U.S. market strategy as it ended its American Depositary Shares program on Nasdaq. The UK-based drugmaker delisted its
Eli Lilly and Company has announced plans to invest more than $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania. The site will be used to produce injectable medicines and devices, including next-generation weight-loss therapies such as
AstraZeneca has announced a $15 billion investment in China through 2030 to expand medicines manufacturing and research and development capabilities, with a strategic focus on cell therapies and radioconjugates. The announcement came on Thursday, 29th January during UK Prime Minister
Boehringer Ingelheim and Simcere Pharmaceutical Group have signed a licence and collaboration agreement to develop SIM0709, a pre-clinical TL1A/IL-23p19 bispecific antibody, for the treatment of inflammatory bowel disease (IBD). The partnership aims to advance the candidate through global development. SIM0709
MS Pharma Group has entered into a strategic partnership with Hetero Group to localize five established biosimilars across oncology, immunology, and hematology in Algeria. The agreement aims to expand access to biologic medicines through a localization and technology transfer approach.
Genentech, a member of the Roche Group, has expanded its investment in a new manufacturing facility in Holly Springs, North Carolina, increasing the total commitment to around $2 billion. The move builds on an initial investment announced in May 2025
Novo Nordisk received FDA approval Monday (22nd December) for oral Wegovy (semaglutide), marking the first oral GLP-1 receptor agonist cleared for obesity treatment. The Danish drugmaker plans a full US launch in early January 2026, with manufacturing underway at its
AstraZeneca announced plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland, including a significant expansion of its flagship biologics facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for clinical supply of molecules
On November 21st 2025 Eli Lilly became the first pharmaceutical company to reach a $1 trillion market valuation this week, worth more than twice the value of any other drugmaker. The company’s stock has soared on the back of the
